Table II.
Association between RUNX2 expression and clinicopathological characteristics of patients with breast cancer.
| Variables | No. of patients (n=67) | Low expression (n=43) | High expression (n=24) | P-value |
|---|---|---|---|---|
| Age, years | 0.800 | |||
| ≤50 | 30 | 20 | 10 | |
| >50 | 37 | 23 | 14 | |
| Subtype | 0.175 | |||
| Lunimal A type | 33 | 25 | 8 | |
| Lunimal B type | 8 | 3 | 5 | |
| HER2 positive | 11 | 6 | 5 | |
| TNBC | 15 | 9 | 6 | |
| Differentiation | 0.120 | |||
| Well and moderately | 40 | 29 | 11 | |
| Poor | 27 | 14 | 13 | |
| Lymph node metastasis | 0.014 | |||
| Present | 45 | 24 | 21 | |
| Absent | 22 | 19 | 3 | |
| Distant metastasis | 0.0004 | |||
| Present | 7 | 0 | 7 | |
| Absent | 60 | 43 | 17 | |
| TNM stage | 0.0005 | |||
| I–II | 44 | 35 | 9 | |
| III–IV | 23 | 8 | 15 |
HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; TNM, tumor, node and metastasis.